Welcome to our dedicated page for Shattuck Labs SEC filings (Ticker: STTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company focused on autoimmune, inflammatory, and other immune-mediated diseases. Through these filings, investors can review how the company reports material events, financing transactions, and governance changes that affect holders of STTK common stock.
Shattuck’s Form 8-K current reports provide details on topics such as private placements of common stock and warrants, the terms of securities purchase agreements, and related registration rights agreements. These filings describe the structure of pre-funded warrants and common warrants, exercise price provisions, beneficial ownership limitations, and expected gross proceeds, as well as the company’s plans to register resales of the underlying shares.
Other 8-K filings furnish press releases announcing quarterly financial results, including research and development and general and administrative expenses, collaboration or license revenue, and net loss figures. While these press releases are often furnished rather than filed for Exchange Act purposes, they offer insight into Shattuck’s cash position and its expectations about how long existing capital and financing arrangements may support operations, subject to the risks noted in its periodic reports.
Filings also address governance matters, such as the resignation and appointment of directors, changes in board size, and committee assignments. For example, Shattuck has reported the addition of new directors associated with a significant private placement and described the rights of certain investors to designate board members under letter agreements.
By reviewing these SEC documents alongside AI-powered summaries, readers can quickly understand the key terms of Shattuck’s financings, the regulatory status of its securities, and the corporate actions that shape its capital structure and oversight. This filings archive complements Shattuck’s scientific and clinical disclosures by showing how those activities are reflected in its official regulatory reporting.
Shattuck Labs (STTK) furnished an update under Item 2.02, announcing it issued a press release with financial results for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1. The company states this information is furnished, not filed, under General Instruction B.2, meaning it is not subject to Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Shattuck Labs, Inc. files a Form S-3 shelf registration that describes an offering including Common Stock, Pre-Funded Warrants and Common Warrants and incorporates by reference prior SEC reports and a Form 8-K filed August 5, 2025. The filing lists a detailed beneficial ownership table showing pre- and post-offering share counts and percentages for multiple investors and insiders, including a holder with 36,879,576 shares (39.35%). The document discloses a securities purchase agreement dated August 4, 2025, exhibits including certificate and bylaw amendments, forms of warrants and registration rights, legal and accounting opinions, and filing fee information. Signatures from the CEO and directors are included with dates in September 2025.
OrbiMed-affiliated entities disclosed acquiring an aggregate of 6,306,127 Shares of Shattuck Labs, representing 9.99% of the outstanding common stock on a post-PIPE basis. The holdings arise from the August 25, 2025 closing of a PIPE in which the issuer sold 15,225,158 Shares and pre-funded warrants and accompanying warrants aggregating potential issuance of 52,635,346 Shares. OrbiMed Private Investments IX, LP (OPI IX) purchased 5,255,106 Shares (≈9.99%) and OrbiMed Genesis Master Fund, L.P. (Genesis) purchased 1,051,021 Shares (≈1.67%).
The PIPE included pre-funded and common warrants but those warrants are subject to an exercise 9.99% blocker and are not presently exercisable. OrbiMed Advisors and its GP entities disclose shared voting and dispositive power over the shares held by the funds and note a board relationship via Director Mona Ashiya, who is obligated to transfer any director equity awards to OrbiMed-affiliated funds. A registration rights agreement was negotiated requiring the issuer to file a resale registration for the PIPE shares.
OrbiMed-affiliated reporting persons purchased securities of Shattuck Labs (STTK) in a private placement that closed on 08/25/2025. They acquired an aggregate of 6,306,127 shares and pre-funded warrants to buy up to 12,133,661 additional shares, plus common warrants exercisable for up to 18,439,799 shares. The price per share with a common warrant was $0.8677 and per pre-funded warrant with a common warrant was $0.8676. The pre-funded warrants are immediately exercisable subject to a 9.99% ownership blocker. Common warrants expire based on clinical-trial data disclosure timing described in the filing.
Shattuck Labs reported a private placement on 08/25/2025 in which accredited investors led by OrbiMed vehicles purchased an aggregate of 6,306,127 shares of common stock and received pre-funded warrants to buy up to 12,133,661 shares plus accompanying common warrants to buy up to 18,439,799 shares. The price per share with an accompanying common warrant was $0.8677; the pre-funded warrant price with an accompanying common warrant was $0.8676. Pre-funded warrants are immediately exercisable subject to a 9.99% beneficial ownership blocker. The report was filed by Mona Ashiya, identified as a director, who disclaims beneficial ownership of the securities except to the extent of pecuniary interest, and the securities are held of record by OrbiMed funds and related entities.
OrbiMed entities and OrbiMed Advisors LLC reported their relationship to Shattuck Labs (STTK) as directors but stated they do not beneficially own any securities of the issuer. The Form 3 lists three reporting entities at the same New York address and indicates the filing covers more than one reporting person. No non‑derivative or derivative holdings are reported.
Dr. Mona Ashiya, a director of Shattuck Labs, Inc. (STTK), was granted a stock option on 08/28/2025 allowing purchase of 66,300 shares of common stock at a $0.99 exercise price. The option vests in three equal annual installments on each of the first three anniversaries of August 28, 2025, is exercisable beginning on those vesting dates, and expires on August 28, 2035. The Form 4 reports 66,300 derivative securities beneficially owned following the transaction, filed by one reporting person and signed by an attorney-in-fact on 09/02/2025. An agreement requires the Reporting Person to transfer any securities or economic benefits from these awards to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC for allocation to OrbiMed Private Investments IX, LP.
Shattuck Labs director Dr. Daniel G. Baker received a stock option award for 66,300 shares of common stock with a $0.99 exercise price on 08/28/2025. The option vests in three equal annual installments beginning on the grant date and is exercisable through 08/28/2035, subject to continued service. The Form 4 was filed on 09/02/2025 and signed by an attorney-in-fact. The disclosure shows an executive compensation action that increases potential common shares outstanding if exercised and ties the director's future economic incentive to the company's stock performance.
Shattuck Labs, Inc. director Dr. Daniel G. Baker has filed an initial insider ownership report on Form 3 for Shattuck Labs, Inc. (STTK). The filing identifies him as a director and indicates that the form is filed by one reporting person. In the remarks section, it explicitly states that no securities are beneficially owned, meaning Dr. Baker reported no direct or indirect ownership of Shattuck Labs securities as of the event date.
Shattuck Labs director Dr. Mona Ashiya filed an initial ownership report on Form 3 for Shattuck Labs, Inc. (STTK). The filing states in the remarks section that no securities are beneficially owned, meaning the reporting person did not report any direct or indirect ownership of Shattuck Labs stock or derivative securities as of the event date.